After a disappointing 2015 which saw the ASX slide by 2%, 2016 has got off to a rather challenging start. That’s because a drop in the value of Chinese stocks has hurt investor sentiment in the ASX and across the globe, with European and US markets also being in the red yesterday. Looking ahead, further volatility seems to be almost inevitable and, as such, many investors may be wary about buying shares at the present time. However, for long term investors, volatility can be a useful ally and can cause high-quality companies to trade at a discount to their intrinsic…
To keep reading, enter your email address or login below.
After a disappointing 2015 which saw the ASX slide by 2%, 2016 has got off to a rather challenging start. That’s because a drop in the value of Chinese stocks has hurt investor sentiment in the ASX and across the globe, with European and US markets also being in the red yesterday.
Looking ahead, further volatility seems to be almost inevitable and, as such, many investors may be wary about buying shares at the present time. However, for long term investors, volatility can be a useful ally and can cause high-quality companies to trade at a discount to their intrinsic values.
For example, health care company CSL Limited (ASX: CSL) offers a superb track record of reliable growth figures, with its bottom line rising at an annualised rate of 15.1% during the last five years. This, plus a beta of just 0.6, indicates that it is less impacted by the macroeconomic outlook than many of its ASX peers and could prove to be a sound, less volatile buy through 2016.
This is emphasised by the fact that CSL generates the majority of its earnings from outside Australia and, if the Chinese economy does continue to falter and hurts the outlook for the Australian economy, a weakening Aussie dollar could cause a boost in CSL’s bottom line. This, alongside the successful integration of CSL’s new influenza vaccine business which was acquired from Novartis, could transform the company’s profitability.
In fact, CSL is forecast to post a rise in its earnings of 26% in financial year 2017 which, alongside a price to earnings (P/E) ratio of 28.4, equates to a price to earnings growth (PEG) ratio of 1.1. This is lower than the ASX’s PEG ratio of 1.4.
Similarly, Coca-Cola Amatil Ltd (ASX: CCL) also appears to be worth buying as the present time, with its transformation strategy set to result in a rise in net profit of 6.3% in financial year 2016. This provides evidence of the progress being made at the company, where costs have been slashed and investment has been made in new products, new marketing tools and also in expanding into Indonesia via a US$500m investment.
While this investment is likely to put Coca-Cola Amatil on a sound long term growth trajectory, in the meantime its appeal as an income stock remains high via a dividend yield of 4.6%. Although interest rate falls may or may not be a feature of 2016, a stable income stream from a dividend which is set to be covered 1.3 times by profit this year should help to keep investor sentiment in Coca-Cola Amatil buoyant.
In addition, Coca-Cola Amatil stated in its first half results that earnings in its alcohol and coffee division increased by 30.4%, which provides it with a degree of diversification and additional growth potential.
With Coca-Cola Amatil strengthening its relationship with Beam Suntory in Australia and New Zealand, it appears poised to continue to deliver upbeat growth over the medium term. And, with it trading on a price to sales (P/S) ratio of 1.4 versus 1.42 for the ASX, it seems to be reasonably priced, too.
Despite this, there are 3 other ASX stocks that I believe could outperform CSL and Coca-Cola Amatil.
In fact, they have recently been named as The Motley Fool's 3 Top Blue-Chips For 2016 and could make a real impact on your bottom line as we move through the year. As a result, it's well worth finding out more about them.
Click here to do so - it's completely free and comes without any obligation.
Motley Fool contributor Peter Stephens has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.